Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2026-03-03 00:00:00 ET · period of report 2026-02-27 · accession 0000882796-26-000011 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-03 | 2026-02-27 | BCRX | Stonehouse Jon P | Dir | A - Grant | $8.75 | +421 | 1.32M | +0.0% | +$3,684 |
| D | 2026-03-03 | 2026-03-02 | BCRX | Stonehouse Jon P | Dir | D - Sale to Iss | $8.64 | -306.0K | 1.32M | -19% | -$2.64M |
| D | 2026-03-03 | 2026-03-02 | BCRX | Stonehouse Jon P | Dir | M - OptEx | $3.22 | +306.0K | 1.63M | +23% | +$985.3K |
| D | 2026-03-03 | 2026-03-02 | BCRX | Stonehouse Jon P | Dir | M - OptEx | $0.00 | -306.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-27 | A | A | 421 | $8.75 | 1,323,850 | D | — | — | (F1) Shares of Common Stock issued to the reporting person in lieu of 50% of the prorated quarterly cash Board Member retainer of $7,375. |
| 2 | Common | Common Stock | 2026-03-02 | D | D | 305,995 | $8.64 | 1,323,850 | D | — | — | (F2) This transaction was made pursuant to a plan adopted by the reporting person on November 28, 2022, as modified on May 13, 2024 and further modified on May 29, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options were originally granted to the reporting person on May 23, 2016 and would have expired on May 23, 2026. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. (F3) The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.54 to $8.81. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-03-02 | M | A | 305,995 | $3.22 | 1,629,845 | D | — | — | (F2) This transaction was made pursuant to a plan adopted by the reporting person on November 28, 2022, as modified on May 13, 2024 and further modified on May 29, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options were originally granted to the reporting person on May 23, 2016 and would have expired on May 23, 2026. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. |
| 4 | Derivative | Emp. Stock Option (Right to Buy) | 2026-03-02 | M | D | 305,995 | $0.00 | 0 | D | $3.22 · 2017-05-23 to 2026-05-23 | 305,995 Common Stock | (F2) This transaction was made pursuant to a plan adopted by the reporting person on November 28, 2022, as modified on May 13, 2024 and further modified on May 29, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options were originally granted to the reporting person on May 23, 2016 and would have expired on May 23, 2026. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. |